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a b s t r a c t
The cytotoxic effects of Bacillus intermedius RNase (binase) towards ovarian cancer cells
(SKOV3 and OVCAR5) were studied in comparison to normal ovarian epithelial cells (HOSE1
andHOSE2). Binase decreased viability and induced the selective apoptosis of ovarian cancer
cells. The apoptosis rate was 50% in SKOV3 and 48% in OVCAR5 cells after 24 h of binase
treatment (50 mg/ml). Binase-induced apoptosis in these cell lines was accompanied by
caspase-3 activation and poly(ADP-ribose) polymerase fragmentation. Normal ovarian
epithelial cellswere not affected by binase, except for a slight decrease of HOSE2 cell viability
and the appearance of traces of activated caspase-3, but not the poly(ADP-ribose) poly-
merase 85-kDA fragment. Binase did not induce alteration of EZH2 (enhancer of zeste-
homolog-2) protein expression neither, in tumor nor in normal cells. In conclusion, selec-
tive binase-induced cell death and apoptosis via poly(ADP-ribose) polymerase fragmenta-
tion may serve as a new treatment option against ovarian cancer progression.
© 2014 Elsevier Ltd. All rights reserved.
1. Introduction
Ovarian cancer affects approximately 1 in 70 women
during their lifetime and is regarded as the most lethal
gynecologic malignancy (Krylova et al., 2006). It takes 7th
place in the list of age-standardized cancer mortality rates
for female population in the world (Ferlay et al., 2013) and
5th place in the USA (Howlader et al., 2012). More than 90%
of ovarian cancers are classiﬁed of epithelial origin. Various
targeted therapeutics e including monoclonal antibodies
against growth factor receptors, inhibitors of tyrosine ki-
nase, poly(ADP-ribose) polymerase (PARP) and angiokinase
e have been explored for ovarian cancer therapy (Campos
and Ghosh, 2010). A novel principle in anticancer therapy
is based on destroying tumor cell RNA by exogenous cyto-
toxic ribonucleases (RNases) (Ardelt et al., 2003; Cabrera-
Fuentes et al., 2012; Fischer et al., 2014, 2013; Leland and
Raines, 2001; Libonati et al., 2008). Some cytotoxic RNases
of bacterial nature, such as Bacillus intermedius e binase
(Cabrera-Fuentes et al., 2013; Makarov and Ilinskaya, 2003;
Makarov et al., 2008), Bacillus amyloliquefaciens e barnase
(Edelweiss et al., 2008; Ulyanova et al., 2011) and Strepto-
myces aureofaciens RNase Sa3 (Sevcik et al., 2002), are not
inhibited by mammalian ribonuclease inhibitor and may
selectively induce apoptosis of different tumor cell lines.
Binase is a well-characterized, highly cationic RNase
that hydrolyzes RNAmolecules, predominantly after purine
(guanine) residues, with formation of 30-mono- and 30-
Abbreviations: Binase, Bacillus intermedius RNase; EOC, Epithelial
ovarian cancer; EZH2, Enhancer of zeste homolog 2 protein; PARP, Pol-
y(ADP-ribose) polymerase; RNase, Ribonuclease.
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